CHAPTER 1 INTRODUCTION

1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 CXperspective

CHAPTER 3 MARKET OVERVIEW

3.1 Market definition and scope
3.2 Key findings

3.2.1 Top investment pockets
3.2.2 Top winning strategies

3.3 Market share analysis, 2015
3.4 Market dynamics

3.4.1 Drivers

3.4.1.1 Increasing incidences of musculoskeletal conditions
3.4.1.2 Technological advancements in medical devices leading ta shift from autograft tallograft
3.4.1.3 Development of biocompatible synthetic bone grafts
3.4.1.4 Obesity and diabetes tincrease the risk of denegenerative joint diseases

3.4.2 Restraints

3.4.2.1 High cost of surgeries
3.4.2.2 Ethical issues related with bone grafting procedures

3.4.3 Opportunities

3.4.3.1 Emerging markets toffer lucrative growth opportunities

3.5 Government Regulations

3.5.1 FDA
3.5.2 Health Canada
3.5.3 CE Mark
3.5.4 Ministry of Health, Labor and Welfare (MHLW)
3.5.5 Therapeutic Goods Administration (TGA)

3.6 Reimbursement Scenario

3.6.1 U.S.
3.6.2 Europe
3.6.3 Asia-Pacific
3.6.4 LAMEA

CHAPTER 4 WORLD BONE GRAFTS AND SUBSTITUTES MARKET, BY PRODUCT

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. ALLOGRAFTS

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Demineralized Bone Matrix (DBM)

4.2.4.1. Market size and forecast

4.2.5. Machined Allografts

4.2.5.1. Market size and forecast

4.3. BONE GRAFT SUBSTITUTES

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Bone Morphogenic Proteins (BMP)

4.3.4.1. Market size and forecast

4.3.5. Synthetic Bone Grafts

4.3.5.1. Market size and forecast

4.4.CELL BASED MATRICES (CBM)

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast

CHAPTER 5 WORLD BONE GRAFTS AND SUBSTITUTES MARKET, BY APPLICATION

5.1 Overview

5.1.1 Market size and forecast

5.2 Spinal Fusion

5.2.1 Market size and forecast

5.3 Trauma

5.3.1 Market size and forecast

5.4 Craniomaxillofacial Surgery

5.4.1 Market size and forecast

5.5 Joint Reconstruction

5.5.1 Market size and forecast

5.6 Dental Bone Grafting

5.6.1 Market size and forecast

CHAPTER 6 WORLD BONE GRAFT AND SUBSTITUTES MARKET, BY REGION

6.1 Overview

6.1.1 Market size and forecast

6.2 North America

6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast
6.2.4 U.S. market size and forecast
6.2.5 Canada market size and forecast
6.2.6 Mexicmarket size and forecast

6.3 Europe

6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Market size and forecast
6.3.4 Germany market size and forecast
6.3.5 France market size and forecast
6.3.6 U.K. market size and forecast
6.3.7 Italy market size and forecast
6.3.8 Spain market size and forecast
6.3.9 Rest of Europe market size and forecast

6.4 Asia-Pacific

6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast
6.4.4 Japan market size and forecast
6.4.5 China market size and forecast
6.4.6 India market size and forecast
6.4.7 Australia market size and forecast
6.4.8 South Korea market size and forecast
6.4.9 Rest of Asia-Pacific market size and forecast

6.5 LAMEA

6.5.1 Key market trends
6.5.2 Key growth factors and opportunities
6.5.3 Market size and forecast
6.5.4 Brazil market size and forecast
6.5.5 South Africa market size and forecast
6.5.6 Saudi Arabia market size and forecast
6.5.7 Israel market size and forecast
6.5.8 Rest of LAMEA market size and forecast

CHAPTER 7 COMPANY PROFILES

7.1 Baxter International Inc.

7.1.1 Company Overview
7.1.2 Company snapshot
7.1.3 Operating business segments
7.1.4 Business performance

7.2 Integra Lifesciences Holdings Corporation

7.2.1 Company overview
7.2.2 Company snapshot
7.2.3 Operating business segments
7.2.4 Business performance
7.2.5 Key strategic moves & developments

7.3 Stryker Corporation

7.3.1 Company overview
7.3.2 Company snapshot
7.3.3 Operating business segments
7.3.4 Business performance
7.3.5 Key strategic moves & developments

7.4 Zimmer Biomet Holdings, Inc.

7.4.1 Company Overview
7.4.2 Company Snapshot
7.4.3 Operating business segments
7.4.4 Business performance
7.4.5 Key Strategic Moves & Developments

7.5 Wright Medical Group N.V.

7.5.1 Company overview
7.5.2 Company snapshot
7.5.3 Operating business segments
7.5.4 Business performance
7.5.5 Key strategic moves & developments

7.6 Xtant Medical Holdings, Inc.

7.6.1 Company overview
7.6.2 Company snapshot
7.6.3 Operating business segments
7.6.4 Business performance
7.6.5 Key strategic moves & developments

7.7 Johnson & Johnson

7.7.1 Company overview
7.7.2 Company snapshot
7.7.3 Operating business segments
7.7.4 Business performance
7.7.5 Key strategic moves & developments

7.8 Arthrex, Inc

7.8.1 Company overview
7.8.2 Company snapshot
7.8.3 Operating business segments
7.8.4 Key strategic moves & developments

7.9 Musculoskeletal Transplant Foundation

7.9.1 Company overview
7.9.2 Company snapshot
7.9.3 Operating business segments

7.10 Medtronic plc

7.10.1 Company Overview
7.10.2 Company Snapshot
7.10.3 Operating Business Segments
7.10.4 Business Performance
7.10.5 Key Strategic Moves & Developments

Other players* in the value chain include:

NovaBone Products
LLC, BonAlive Biomaterials Ltd.
Sigma Graft Biomaterials
Pioneer Surgical Technology Inc.
RTI Biologics, Inc.
Orthofix International N.V.
Citagenix Inc.
Heraeus Medical GmbH
Graftys SA
NuVasive, Inc.

*Profiles of these players are not included. The same will be included on request.